1. Pooled analysis of TNF inhibitor biosimilar studies comparing radiographic progression by disease activity states in rheumatoid arthritis
- Author
-
Michael E. Weinblatt, Edward C. Keystone, Gihyun Myung, Paul Emery, Inyoung Baek, Jeehoon Ghil, Evelyn Hong, Jung-Yoon Choe, Mark C. Genovese, and Josef S Smolen
- Subjects
Adult ,Male ,medicine.medical_specialty ,medicine.medical_treatment ,Radiography ,Immunology ,lcsh:Medicine ,Arthritis ,Rheumatoid Arthritis ,DMARDs (biologic) ,Severity of Illness Index ,Gastroenterology ,Etanercept ,Arthritis, Rheumatoid ,Rheumatology ,Internal medicine ,medicine ,Adalimumab ,Humans ,Immunology and Allergy ,skin and connective tissue diseases ,Biosimilar Pharmaceuticals ,Aged ,medicine.diagnostic_test ,business.industry ,Remission Induction ,lcsh:R ,anti-TNF ,Middle Aged ,medicine.disease ,Infliximab ,TNF inhibitor ,Logistic Models ,arthritis ,Antirheumatic Agents ,Erythrocyte sedimentation rate ,Rheumatoid arthritis ,Disease Progression ,Female ,Tumor Necrosis Factor Inhibitors ,business ,medicine.drug - Abstract
ObjectiveTo evaluate the relationship between disease activity and radiographic progression in rheumatoid arthritis, three phase III studies of SB4, SB2 and SB5 (biosimilars of etanercept, infliximab and adalimumab) were pooled to assess radiographic progression by disease activity status.MethodsPatients from each study with radiographic data were pooled and grouped based on disease activity state (remission, low disease activity (LDA), moderate disease activity (MDA) and high disease activity (HDA)), determined by disease activity score based on 28-joint count (DAS28) per erythrocyte sedimentation rate, Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) at different time points. Mean change in modified Total Sharp Score (mTSS) and the proportion of radiographic non-progressors of higher disease activity groups (LDA, MDA and HDA) in reference to remission were summarised descriptively, with comparison of ORs using logistic models.Results1265 patients were included. In all treatments combined, the 1 year mean change in mTSS was 0.03, 0.4, 0.3 and 1.3 and proportion of radiographic non-progressors was 79.8%, 78.1%, 74.1% and 58.4% in the week 24/30 DAS28-determined remission, LDA, MDA and HDA groups, respectively. ORs (95% CIs) of the proportion of non-progressors were lowest in the HDA group in reference to remission (0.35 (0.23 to 0.54)), followed by MDA (0.72 (0.50 to 1.05)) and LDA (0.90 (0.55 to 1.48)) groups. Similar trends were observed when disease activity was assessed using SDAI or CDAI.ConclusionA pooled analysis of radiographic assessment data from three biosimilar studies showed that radiographic progression is small overall but increases with worse disease activity.Trial registration numbersNCT01895309, NCT01936181 and NCT02167139
- Published
- 2020